Text Size

Effect of Renal Impairment on the Pharmacokinetics of NN9535

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00833716
First received: January 29, 2009
Last updated: July 5, 2012
Last verified: March 2012
History of Changes
  Purpose

This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.


Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Renal Impairment
 Drug: NN9535
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • AUC of NN9535 [ Time Frame: at 21 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Laboratory safety, adverse events [ Time Frame: at 21 days ] [ Designated as safety issue: Yes ]

Enrollment: 62
Study Start Date: February 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NN9535
10 mg/mL of NN9535 solution for s.c. injection, single dose

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • Subjects meeting the pre-defined GFR (glomerular filtration rate) criteria (estimated by the Cockcroft & Gault formula) for any of the renal function groups
  • Body Mass Index (BMI) equal to or less than 40kg/m2

Exclusion Criteria:

  • Known or suspected allergy to trial product(s) or related products
  • Renal transplanted patients
  • Certain cardiac problems (heart failure, unstable angina, MI (myocardial infarction) within the last 3 months)
  • Known current hepatic dysfunction or severe hepatic disease during the last 12 months
  • Female of childbearing potential/breast feeding
  • History of alcoholism or drug abuse
  • Blood donation during the last 8 weeks prior to the study
  • Past or current history of pancreatitis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00833716

Locations
United States, Florida
Novo Nordisk Clinical Trial Call Center
Miami, Florida, United States, 33014
Novo Nordisk Clinical Trial Call Center
Orlando, Florida, United States, 32806
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: D J Chatterjee, PhD Novo Nordisk
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Novo Nordisk
ClinicalTrials.gov Identifier: NCT00833716     History of Changes
Other Study ID Numbers: NN9535-3616
Study First Received: January 29, 2009
Last Updated: July 5, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Renal Insufficiency
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 16, 2013